[go: up one dir, main page]

MX2017014095A - Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad. - Google Patents

Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad.

Info

Publication number
MX2017014095A
MX2017014095A MX2017014095A MX2017014095A MX2017014095A MX 2017014095 A MX2017014095 A MX 2017014095A MX 2017014095 A MX2017014095 A MX 2017014095A MX 2017014095 A MX2017014095 A MX 2017014095A MX 2017014095 A MX2017014095 A MX 2017014095A
Authority
MX
Mexico
Prior art keywords
cholesterol levels
density lipoprotein
lipoprotein cholesterol
lowering low
lowering
Prior art date
Application number
MX2017014095A
Other languages
English (en)
Other versions
MX385941B (es
Inventor
Liu Yang
Zheng Pan
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of MX2017014095A publication Critical patent/MX2017014095A/es
Publication of MX385941B publication Critical patent/MX385941B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La presente invención se refiere al uso de una proteína CD24 para bajar los niveles de colesterol de las lipoproteínas de baja densidad, el tratamiento y la prevención de la aterosclerosis, y a la reducción de riesgo de enfermedad cardiovascular.
MX2017014095A 2015-05-07 2016-05-06 Uso de cd24 para disminuir los niveles de colesterol de las lipoproteínas de baja densidad. MX385941B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07
PCT/US2016/031109 WO2016179456A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Publications (2)

Publication Number Publication Date
MX2017014095A true MX2017014095A (es) 2018-03-16
MX385941B MX385941B (es) 2025-03-18

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014095A MX385941B (es) 2015-05-07 2016-05-06 Uso de cd24 para disminuir los niveles de colesterol de las lipoproteínas de baja densidad.

Country Status (18)

Country Link
US (2) US10369197B2 (es)
EP (1) EP3292144B1 (es)
JP (1) JP6751756B2 (es)
KR (1) KR20170141216A (es)
CN (1) CN107531772B (es)
AU (1) AU2016258084B2 (es)
BR (1) BR112017022394A2 (es)
CA (1) CA2982612A1 (es)
EA (1) EA038520B1 (es)
ES (1) ES2829235T3 (es)
HK (1) HK1249521A1 (es)
HR (1) HRP20201651T1 (es)
HU (1) HUE051866T2 (es)
IL (1) IL255086B (es)
MX (1) MX385941B (es)
PT (1) PT3292144T (es)
WO (1) WO2016179456A1 (es)
ZA (1) ZA201706846B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531772B (zh) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Cd24用于降低低密度脂蛋白胆固醇水平的用途
AU2018231166A1 (en) * 2017-03-07 2019-09-26 Oncoimmune, Inc. Methods of use of soluble CD24 for treating systemic lupus erythematosus
US20190248881A1 (en) * 2017-12-04 2019-08-15 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
JP2021523929A (ja) * 2018-03-05 2021-09-09 オンコイミューン， インコーポレイテッド 後天性免疫不全症候群（ｈｉｖ／ａｉｄｓ）の治療のための可溶性ｃｄ２４の使用方法
KR20210018294A (ko) * 2018-06-04 2021-02-17 온코이뮨, 아이앤씨. 이식편 대 숙주 질환 및 점막염의 예방 및 치료를 위한 cd24의 사용 방법
SG11202103334YA (en) 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
AU2020219785A1 (en) * 2019-02-06 2021-09-02 Children's Research Institute, Children's National Medical Center Targeting CD24-Siglec interactions for treating subjects with prediabetes or diabetes
US20220000973A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis
US20230103352A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection
EP4103217A4 (en) * 2020-02-10 2024-03-13 Oncoimmune Inc. METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
DK1267909T3 (da) * 2000-03-29 2010-11-08 Univ Ohio State Res Found Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler
CN1323544A (zh) * 2000-05-13 2001-11-28 蛋白质技术国际公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
JP2011509244A (ja) * 2007-12-21 2011-03-24 ユニバーシティー オブ ロチェスター 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのｃｄ２４
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2012170974A1 (en) * 2011-06-10 2012-12-13 The Trustees Of The University Of Pennsylvania System and method of cytomic vascular health profiling
CN107531772B (zh) * 2015-05-07 2021-09-21 肿瘤免疫股份有限公司 Cd24用于降低低密度脂蛋白胆固醇水平的用途

Also Published As

Publication number Publication date
JP6751756B2 (ja) 2020-09-09
EA201792418A1 (ru) 2018-02-28
EA038520B1 (ru) 2021-09-09
EP3292144A4 (en) 2018-11-14
ZA201706846B (en) 2018-12-19
US20190307841A1 (en) 2019-10-10
AU2016258084B2 (en) 2020-01-30
AU2016258084A1 (en) 2017-11-02
MX385941B (es) 2025-03-18
HK1249521A1 (zh) 2018-11-02
EP3292144B1 (en) 2020-08-26
ES2829235T3 (es) 2021-05-31
IL255086B (en) 2021-08-31
US11026995B2 (en) 2021-06-08
CN107531772B (zh) 2021-09-21
CN107531772A (zh) 2018-01-02
US10369197B2 (en) 2019-08-06
BR112017022394A2 (pt) 2018-07-17
WO2016179456A1 (en) 2016-11-10
HRP20201651T1 (hr) 2020-12-25
EP3292144A1 (en) 2018-03-14
IL255086A0 (en) 2017-12-31
PT3292144T (pt) 2020-11-05
JP2018515605A (ja) 2018-06-14
CA2982612A1 (en) 2016-11-10
HUE051866T2 (hu) 2021-03-29
US20180110828A1 (en) 2018-04-26
KR20170141216A (ko) 2017-12-22

Similar Documents

Publication Publication Date Title
MX2017014095A (es) Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad.
EP3538078A4 (en) FORMULATIONS FOR EFFICIENT CANNABINOID DELIVERY
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
IL262591A (en) Methods for treating patients with familial hypercholesterolemia
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
EP3015114C0 (en) OIL-IN-WATER EMULSION NOT CONTAINING SURFACTANT, AND ITS USE
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados
DK3212208T3 (da) Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet
MX2015003140A (es) Formulaciones de enzalutamida.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
DK3395353T3 (da) Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
EP3154591C0 (en) PHOSPHOLIPID COMPOSITION, AND MICROBUBLES AND EMULSIONS FORMED USING THE SAME
ES2899185T8 (es) Cepas probióticas que tienen capacidad de absorción de colesterol, procedimientos y usos de las mismas
EP3530264A4 (en) OIL-IN-WATER-TYPE EMULSION COMPOSITION
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
MX392383B (es) Metodos para tratar afecciones oculares.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
CL2018003792A1 (es) Procedimiento para enfriamineto de elementos de madera acetilada.
ECSP17018513A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
BR112017026807A2 (pt) agentes solubilizantes para compostos ativos funcionais
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
CL2014001127A1 (es) Metodos y composicion de fumigante que comprende hexafluoropropeno, 1,1,3,3,3-pentafluoropropeno o combinacion de los mismos.